Together, on Agena’s MassARRAY System this technology allows labs to deliver reliable results to patients quickly and economically. He explained that a PCR reaction targets the DNA area of interest and the mass spectrometer provides a measurement based on mass rather than fluorescence. We look forward to working with the Mesa team to expand the applications we deliver and innovate new technologies for clinical genomics.”įounded in 2014, Agena Bioscience has nearly 200 employees and its customers include some of the largest and most prestigious molecular genetics and public health laboratories.ĭansky said that they are the only company in the world that uses a combination of mass spectroscopy and multiplex PCR in genetic testing. “We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. “Our robust technology platform along with deep customer partnership has been the foundation of our success,” Dansky said. 31, 2021.Īgena Bio’s CEO, Pete Dansky will head up the new Clinical Genomics Division at Mesa. The transaction is expected to be completed by the end of this year during Mesa’s third fiscal quarter ending Dec. Agena is a private molecular diagnostics tools company that develops, manufactures and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions.Īt the close of the deal, Agena will remain in San Diego and become Mesa Lab’s new Clinical Genomics Division. that designs and manufactures critical quality control solutions for the pharmaceutical, healthcare and medical device industries.
Mesa Labs is a public company based in Lakewood, Colo.
0 kommentar(er)
